Health Care › Biological Products (No Diagnostic Substances)
BIIB Stock Price Correlated With Biogen Financials
External Links ⌄
Income Statement
Cash Flow
Balance Sheet
BIIB Income Statement
Enable JavaScript and reload
Revenue, Net:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
BIIB Cash Flow
Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:
BIIB Balance Sheet
Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:
COMPANY PROFILE
1.
Business
Overview
Overview
Biogen Idec is a global biotechnology company that creates new
standards of care in therapeutic areas with high unmet medical
needs. We currently have four marketed products: AVONEX,
RITUXAN, TYSABRI, and FUMADERM. Our marketed products are used
for the treatment of multiple sclerosis (MS), non-Hodgkin’s
lymphoma (NHL), rheumatoid arthritis (RA), Crohn’s disease,
chronic lymphocytic leukemia and psoriasis.
Basis
of Presentation
In the opinion of management, the accompanying unaudited
consolidated financial statements include all adjustments,
consisting of normal recurring accruals, necessary for a fair
presentation of our financial statements for interim periods in
accordance with accounting principles generally accepted in the
United States (U.S. GAAP). The information included in this
quarterly report on
Form 10-Q
should be read in conjunction with our consolidated financial
statements and the accompanying notes included in our Annual
Report on
Form 10-K
for the year ended December 31, 2009 (2009 Form 10-K).
Our accounting policies are described in the “Notes to
Consolidated Financial Statements” in our 2009
Form 10-K
and updated, as necessary, in this
Form 10-Q.
The year-end consolidated balance sheet data presented for
comparative purposes was derived from audited financial
statements, but does not include all disclosures required by
U.S. GAAP. The results of operations for the three months
ended March 31, 2010 are not necessarily indicative of the
operating results for the full year or for any other subsequent
interim period.
Consolidation
Our consolidated financial statements reflect our financial
statements, those of our wholly-owned subsidiaries, certain
variable interest entities in which we are the primary
beneficiary and those of our joint ventures in Italy and
Switzerland, Biogen Dompé SRL and Biogen Dompé
Switzerland GmbH, respectively. For such consolidated entities
in which we own less than a 100% interest, we record net income
(loss) attributable to noncontrolling interest in our
consolidated statements of income equal to the percentage of the
economic or ownership interest retained in the collaborative
arrangement or joint venture by the respective noncontrolling
parties. All material intercompany balances and transactions
have been eliminated in consolidation.
In determining whether we are the primary beneficiary, we
consider a number of factors, including our ability to direct
the activities that most significantly affect the entity’s
economic success, our contractual rights and responsibilities
under the arrangement and the significance of the arrangement to
each party. These considerations impact the way we account for
our existing collaborative and joint venture relationships and
may result in the future consolidation of companies or entities
with which we have collaborative or other arrangements.
Use of
Estimates
The preparation of consolidated financial statements in
accordance with U.S. GAAP requires management to make
estimates and judgments that may affect the reported amounts of
assets, liabilities, revenues and expenses, and related
disclosure of contingent assets and liabilities. On an on-going
basis, we evaluate our estimates and judgments, including those
related to revenue recognition and related allowances,
marketable securities, derivatives and hedging activities,
inventory, impairments of long-lived assets including intangible
assets, impairments of goodwill, the consolidation of variable
interest entities, income taxes including the valuation
allowance for deferred t
Business
Overview
Overview
Biogen Idec is a global biotechnology company that creates new
standards of care in therapeutic areas with high unmet medical
needs. We currently have four marketed products: AVONEX,
RITUXAN, TYSABRI, and FUMADERM. Our marketed products are used
for the treatment of multiple sclerosis (MS), non-Hodgkin’s
lymphoma (NHL), rheumatoid arthritis (RA), Crohn’s disease,
chronic lymphocytic leukemia and psoriasis.
Basis
of Presentation
In the opinion of management, the accompanying unaudited
consolidated financial statements include all adjustments,
consisting of normal recurring accruals, necessary for a fair
presentation of our financial statements for interim periods in
accordance with accounting principles generally accepted in the
United States (U.S. GAAP). The information included in this
quarterly report on
Form 10-Q
should be read in conjunction with our consolidated financial
statements and the accompanying notes included in our Annual
Report on
Form 10-K
for the year ended December 31, 2009 (2009 Form 10-K).
Our accounting policies are described in the “Notes to
Consolidated Financial Statements” in our 2009
Form 10-K
and updated, as necessary, in this
Form 10-Q.
The year-end consolidated balance sheet data presented for
comparative purposes was derived from audited financial
statements, but does not include all disclosures required by
U.S. GAAP. The results of operations for the three months
ended March 31, 2010 are not necessarily indicative of the
operating results for the full year or for any other subsequent
interim period.
Consolidation
Our consolidated financial statements reflect our financial
statements, those of our wholly-owned subsidiaries, certain
variable interest entities in which we are the primary
beneficiary and those of our joint ventures in Italy and
Switzerland, Biogen Dompé SRL and Biogen Dompé
Switzerland GmbH, respectively. For such consolidated entities
in which we own less than a 100% interest, we record net income
(loss) attributable to noncontrolling interest in our
consolidated statements of income equal to the percentage of the
economic or ownership interest retained in the collaborative
arrangement or joint venture by the respective noncontrolling
parties. All material intercompany balances and transactions
have been eliminated in consolidation.
In determining whether we are the primary beneficiary, we
consider a number of factors, including our ability to direct
the activities that most significantly affect the entity’s
economic success, our contractual rights and responsibilities
under the arrangement and the significance of the arrangement to
each party. These considerations impact the way we account for
our existing collaborative and joint venture relationships and
may result in the future consolidation of companies or entities
with which we have collaborative or other arrangements.
Use of
Estimates
The preparation of consolidated financial statements in
accordance with U.S. GAAP requires management to make
estimates and judgments that may affect the reported amounts of
assets, liabilities, revenues and expenses, and related
disclosure of contingent assets and liabilities. On an on-going
basis, we evaluate our estimates and judgments, including those
related to revenue recognition and related allowances,
marketable securities, derivatives and hedging activities,
inventory, impairments of long-lived assets including intangible
assets, impairments of goodwill, the consolidation of variable
interest entities, income taxes including the valuation
allowance for deferred t
Free historical financial statements for Biogen Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 59 quarters since 2010. Compare with BIIB stock chart to see long term trends.
Data imported from Biogen Inc SEC filings. Check original filings before making any investment decision.